Vicenin 2 isolated from Artemisia capillaris exhibited potent anti-glycation properties

Food and Chemical Toxicology

Volumn 69, Issue , 2014, Pages 55-62

  Islam, Md Nurul ^a   Ishita, Ishrat Jahan ^a   Jung, Hyun Ah ^b   Choi, Jae Sue ^a  

^a Pukyong National University   (South Korea)

^b Chonbuk National University   (South Korea)

Author keywords

Advanced glycation end products; Aldose reductase; Anti diabetic; Protein tyrosine phosphatase 1B; Vicenin 2; Glucosidase

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ALDEHYDE REDUCTASE; ALPHA GLUCOSIDASE; ARTEMISIA CAPILLARIS EXTRACT; BOVINE SERUM ALBUMIN; CARBONYL DERIVATIVE; FRUCTOSAMINE; PROTEIN TYROSINE PHOSPHATASE 1B; QUERCETIN; RAT LENS ALDOSE REDUCTASE; THIOL GROUP; UNCLASSIFIED DRUG; VICENIN 2; AMYLOID; APIGENIN; APIGENIN-6,8-DI-C-GLYCOPYRANOSIDE; ENZYME INHIBITOR; GLUCOSIDE; GLYCOSIDASE INHIBITOR; LYSINE; N(6)-CARBOXYMETHYLLYSINE;

ANIMAL TISSUE; ANTIDIABETIC ACTIVITY; ARTEMISIA; ARTEMISIA CAPILLARIS; ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG POTENCY; DRUG STRUCTURE; ENZYME INHIBITION; ENZYME METABOLISM; GLYCOSYLATION; IN VITRO STUDY; NONHUMAN; PROTEIN MODIFICATION; RAT; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMISTRY; DRUG EFFECTS; ENZYMOLOGY; ISOLATION AND PURIFICATION; LENS; MEDICINAL PLANT; METABOLISM; OXIDATION REDUCTION REACTION; PROTEIN CARBONYLATION; SPRAGUE DAWLEY RAT;

ALDEHYDE REDUCTASE; ALPHA-GLUCOSIDASES; AMYLOID; ANIMALS; APIGENIN; ARTEMISIA; ENZYME INHIBITORS; FRUCTOSAMINE; GLUCOSIDES; GLYCOSIDE HYDROLASE INHIBITORS; GLYCOSYLATION END PRODUCTS, ADVANCED; LENS, CRYSTALLINE; LYSINE; OXIDATION-REDUCTION; PLANTS, MEDICINAL; PROTEIN CARBONYLATION; PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 1; RATS, SPRAGUE-DAWLEY; SERUM ALBUMIN, BOVINE;

EID: 84899115496     PISSN: 02786915     EISSN: 18736351     Source Type: Journal    
DOI: 10.1016/j.fct.2014.03.042     Document Type: Article

References (61)

1. Ahmed N. Advanced glycation endproducts - role in pathology of diabetic complications. Diabetes Res. Clin. Pract. 2005, 67:3-21.
2. Ardestani A., Yazdanparast R. Cyperus rotundus suppresses age formation and protein oxidation in a model of fructose-mediated protein glycoxidation. Int. J. Biol. Macromol. 2007, 41:572-578.
3. Baron A.D. Postprandial hyperglycaemia and α-glucosidase inhibitors. Diabetes Res. Clin. Pract. 1998, 40:51-55.
4. Benalla W., Bellahcen S., Bnouham M. Antidiabetic medicinal plants as a source of alpha glucosidase inhibitors. Curr. Diabetes Rev. 2010, 6:247-254.
5. Bhat M., Zingarde S.S., Bhargava S.Y., Kumar A.R., Joshi B.N. Antidiabetic Indian plants: a good source of potent amylase inhibitors. Evid. Based Complement. Alternat. Med. 2011, http://dx.doi.org/10.1093/ecam/nen040.
6. Bonora E., Muggeo M. Postprandial blood glucose as a risk factor for cardiovascular disease in type II diabetes: the epidemiological evidences. Diabetologia 2001, 44:2107-2114.
7. Booth A.A., Khalifah R.G., Todd P., Hudson B.G. In vitro kinetic studies of formation of antigenic advanced glycation end products (AGEs). J. Biol. Chem. 1997, 272:5430-5437.
8. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001, 414:813-820.
9. Bucala R., Cerami A. Advanced glycosylation: chemistry, biology, and implications for diabetes and aging. Adv. Pharmacol. 1992, 23:1-34.
10. Buchwald-Werner S., Fujii H. Prokinetic and antispasmodic constituent discovered in Perilla frutescens - development of a gut health ingredient. Planta Med. 2012, 78:CL61.
11. Charron M.J., Dubin R.A., Michels C.A. Structural and functional analysis of the MAL1 locus of Saccharomyces cerevisiae. Mol. Cell. Biol. 1986, 6:3891-3899.
12. Cheng A.Y., Fantus I.G. Oral antihyperglycemic therapy for type 2 diabetes mellitus. Can. Med. Assoc. J. 2005, 172:213-226.
13. Choi J.S., Islam M.N., Ali M.Y., Kim E.J., Kim Y.M., Jung H.A. Effects of C-glycosylation on anti-diabetic, anti-Alzheimer's disease and anti-inflammatory potential of apigenin. Food Chem. Toxicol. 2013, 64:27-33.
14. Chylack L.T., Kinoshita J.H. A biochemical evaluation of a cataract induced in a high-glucose medium. Invest. Ophthalmol. 1969, 8:401-412.
15. Cui L., Na M.K., Oh H., Bae E.Y., Jeong D.G., Ryu S.E., Kim S., Kim B.Y., Oha W.K., Ahn J.S. Protein tyrosine phosphatase 1B inhibitors from Morus root bark. Bioorg. Med. Chem. Lett. 2006, 16:1426-1429.
16. Elchebly M., Payette P., Michaliszyn E., Cromlish W., Collins S., Loy A.L., Normandin D., Cheng A., Himms-Hagen J., Chan C.C., Ramachandran C., Gresser M.J., Tremblay M.L., Kennedy B.P. Increased insulin sensitivity and obesity resistance in mice lacking the protein tyrosine phosphatase-1B gene. Science 1999, 283:1544-1548.
17. Ellman G.L. Tissue sulfhydryl groups. Arch. Biochem. Biophys. 1959, 82:70-77.
18. Eugen J.V., Hajime F., Kohei H., Sybille B.W. Testing of Perilla frutescens extract and vicenin 2 for their antispasmodic effect. Phytomedicine 2013, 20:427-431.
19. Ferrannini E., Solini A. SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects. Nat. Rev. Endocrinol. 2012, 8:495-502.
20. Goldstein B.J., Bitter-Kowalczyk A., White M.F., Harbeck M. Tyrosine dephosphorylation and deactivation of insulin receptor substrate-1 by protein tyrosine phosphatase 1B. Possible facilitation by the formation of a ternary complex with the GRB2 adaptor protein. J. Biol. Chem. 2000, 275:4283-4289.
21. Grael C.F.F., Albuquerque S., Lopesa J.L.C. Chemical constituents of Lychnophora pohlii and trypanocidal activity of crude plant extracts and of isolated compounds. Fitoterapia 2005, 76:73-82.
22. Hammes H.P., Alt A., Niwa T., Clausen J.T., Bretzel R.G., Brownlee M., Schleicher E.D. Differential accumulation of advanced glycation end products in the course of diabetic retinopathy. Diabetologia 1999, 42:728-736.
23. Hayman S., Kinoshita J.H. Isolation and properties of lens aldose reductase. J. Biol. Chem. 1965, 240:877-882.
24. Hoffmann-Bohm K., Lotter H., Seligmann O., Wagner H. Antihepatotoxic C-glycosylflavones from the leaves of Allophyllus edulis var. edulis and gracilis. Planta Med. 1992, 58:544-548.
25. Huijberts M.S.P., Schaper N.C.S., Schalkwijk C.G. Advanced glycation end products and diabetic foot disease. Diabetes Metab. Res. Rev. 2008, 24:S19-S24.
26. International Diabetes Federation IDF Diabetes Atlas 2013, International Diabetes Federation, Brussels, Belgium. sixth ed.
27. Islam M.N., Jung H.A., Sohn H.S., Kim H.M., Choi J.S. Potent α-glucosidase and protein tyrosine phosphatase 1B inhibitors from Artemisia capillaris. Arch. Pharm. Res. 2013, 36:542-552.
28. Jackson G.S., Clarke A.R. Mammalian prion proteins. Curr. Opin. Struct. Biol. 2000, 10:69-74.
29. Jakus V., Rietbrock N. Advanced glycation end-products and the progress of diabetic vascular complications. Physiol. Res. 2004, 53:131-142.
30. Jez J.M., Bennett M.J., Schlegel B.P., Lewis M., Penning T.M. Comparative anatomy of the aldo-keto reductase superfamily. Biochem. J. 1997, 326:625-636.
31. Johnson T.O., Ermolieff J., Jirousek M.R. Protein tyrosine phosphatase 1B inhibitors for diabetes. Nat. Rev. Drug Discov. 2002, 1:696-709.
32. Jung H.A., Park J.J., Islam M.N., Jin S.E., Min B.S., Lee J.H., Sohn H.S., Choi J.S. Inhibitory activity of coumarins from Artemisia capillaris against advanced glycation endproduct formation. Arch. Pharm. Res. 2012, 35:1021-1035.
33. Karachalias N., Babaei-Jadidi R., Ahmed N., Thornalley P.J. Accumulation of frucotsyl-lysine and advanced glycation end products in the kidney, retina and peripheral nerve of streptozotocin-induced diabetic rats. Biochem. Soc. Trans. 2003, 31:1423-1425.
34. Kinoshita J.H., Nishimura C. The involvement of aldose reductase in diabetic complications. Diabetes Metab. Rev. 1998, 4:323-337.
35. Klaman L.D., Boss O., Peroni O.D., Kim J.K., Martino J.L., Zabolotny J.M., Moghal N., Lubkin M., Kim Y.B., Sharpe A.H., Stricker-Krongrad A., Shulman G.I., Neel B.G., Kahn B.B. Increased energy expenditure, decreased adiposity, and tissue-specific insulin sensitivity in protein-tyrosine phosphatase 1B-deficient mice. Mol. Cell. Biol. 2000, 20:5479-5489.
36. Lassila M., Seah K.K., Allen T.J., Thallas V., Thomas M.C., Candido R., Burns W.C., Forbes J.M., Calkin A.C., Cooper M.E., Jandeleit-Dahm K.A. Accelerated nephropathy in diabetic apolipoprotein E-knockout mouse: role of advanced glycation end products. J. Am. Soc. Nephrol. 2004, 15:2125-2138.
37. Lebovitz H.E. Alpha-glucosidase inhibitors. Endocrinol. Metabol. Clin. North Am. 1997, 26:539-551.
38. Levine R.L., Garland D., Oliver C.N., Amici A., Climent I., Lenz A.G., Ahn B.W., Shaltiel S., Stadtman E.R. Determination of carbonyl content in oxidatively modified proteins. Methods Enzymol. 1990, 186:464-478.
39. Li T., Zhang X.D., Song Y.W., Liu J.W. A microplate-based screening method for α-glucosidase inhibitors. Chin. J. Clin. Pharmacol. Therap. 2005, 10:1128-1134.
40. Marrassini C., Davicino R., Acevedo C., Anesini C., Gorzalczany S., Ferraro G. Vicenin-2, a potential anti-inflammatory constituent of Urtica circularis. J. Nat. Prod. 2011, 74:1503-1507.
41. Marzban L., Soukhatcheva G., Verchere C.B. Role of carboxypeptidase E in processing of pro-islet amyloid polypeptide in β-cells. Endocrinology 2005, 146:1808-1817.
42. Munch G., Thome J., Foley P., Schinzel R., Riederer P. Advanced glycation endproducts in ageing and Alzheimer's disease. Brain Res. 1997, 23:134-143.
43. Nagaprashantha L.D., Vatsyayan R., Singhal J., Fast S., Roby R., Awasthi S., Singhal S.S. Anti-cancer effects of novel flavonoid vicenin-2 as a single agent and in synergistic combination with docetaxel in prostate cancer. Biochem. Pharmacol. 2011, 82:1100-1109.
44. Okado A., Kawasaki Y., Hasuike Y., Takahashi M., Teshima T., Fujii J., Taniguchi N. Induction of apoptotic cell death by methylglyoxal and 3-deoxyglucosone in macrophage-derived cell lines. Biochem. Biophys. Res. Commun. 1996, 225:219-224.
45. Puls W., Krause H.P., Müller L., Schutt H., Sitt R., Thomas G. Inhibitors of the rate of carbohydrate and lipid absorption by the intestine. Int. J. Obes. 1984, 8:181-190.
46. Ramirez M.A., Borja N.L. Epalrestat: an aldose reductase inhibitor for the treatment of diabetic neuropathy. Pharmacotherapy 2008, 28:646-655.
47. Resnick H.E., Foster G.L., Bardsley J., Ratner R.E. Achievement of American Diabetes Association clinical practice recommendations among US adults with diabetes, 1999-2002: the National Health and Nutrition Examination Survey. Diabetes Care 2006, 29:531-537.
48. Shield J.P., Poyser K., Hunt L., Pennock C.A. Fructosamine and glycated haemoglobin in the assessment of long term glycaemic control in diabetes. Arch. Dis. Child. 1994, 71:443-445.
49. Stefek M. Natural flavonoids as potential multifunctional agents in prevention of diabetic cataract. Interdiscip. Toxicol. 2011, 4:69-77.
50. Suen C.S., Burn P. The potential of incretin-based therapies in type 1 diabetes. Drug Discov. Today 2012, 17:89-95.
51. Takahashi M., Kushida K., Ohishi T., Kawana K., Hoshino H., Uchiyama A., Inoue T. Quantitative analysis of crosslinks pyridinoline and pentosidine in articular cartilage of patients with bone and joint disorders. Arthritis Rheum. 1994, 37:724-728.
52. Tan S.Y., Pepys M.B. Amyloidosis. Histopathology 1994, 25:403-414.
53. Tanji N., Markowitz G.S., Fu C., Kislinger T., Taguchi A., Pischetsrieder M., Stern D., Schmidt A.M., D'Agati V.D. Expression of advanced glycation end products and their cellular receptor RAGE in diabetic nephropathy and nondiabetic renal disease. J. Am. Soc. Nephrol. 2000, 11:1656-1666.
54. Telci A., Çakatay U., Salman S., Satman I., Sivas A. Oxidative protein damage in early stage type 1 diabetic patients. Diabetes Res. Clin. Pract. 2000, 50:213-223.
55. Tupe R.S., Agte V.V. Role of zinc along with ascorbic acid and folic acid during long-term in vitro albumin glycation. Br. J. Nutr. 2010, 103:370-377.
56. Valencia J.V., Mone M., Zhang J., Weetall M., Buxton F.P., Hughes T.E. Divergent pathways of gene expression are activated by the RAGE ligands S100b and AGE-BSA. Diabetes 2004, 53:743-751.
57. Velozo L.S.M., Ferreira M.J.P., Santos M.I.S., Moreira D.L., Guimarães E.F., Emerenciano V.P., Kaplan M.A.C. C-glycosyl flavones from Peperomia blanda. Fitoterapia 2009, 80:119-122.
58. Vinson J.A., Howard T.B. Inhibition of protein glycation and advanced glycation end products by ascorbic acid and other vitamins and nutrients. J. Nutr. Biochem. 1996, 7:659-663.
59. Wendt T.M., Tanji N., Guo J., Kislinger T.R., Qu W., Lu Y., Bucciarelli L.G., Rong L.L., Moser B., Markowitz G.S., Stein G., Bierhaus A., Liliensiek B., Arnold B., Nawroth P.P., Stern D.M., D'Agati V.D., Schmidt A.M. RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy. Am. J. Pathol. 2003, 162:1123-1137.
60. Wu X., Hoffstedt J., Deeb W., Singh R., Sedkova N., Zilbering A., Zhu L., Park P.K., Arner P., Goldstein B.J. Depot-specific variation in protein tyrosine phosphatases activities in human omental and subcutaneous adipose tissue: a potential contribution to differential insulin sensitivity. J. Clin. Endocrinol. Metab. 2001, 86:5973-5980.
61. Zhang Z.Y., Lee S.Y. PTP1B inhibitors as potential therapeutics in the treatment of type 2 diabetes and obesity. Expert Opin. Invest. Drugs 2003, 12:223-233.